These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29991292)

  • 21. Synthesis, biochemical evaluation, and molecular modeling of organophosphate-coumarin hybrids as potent and selective butyrylcholinesterase inhibitors.
    Macklin LJ; Schwans JP
    Bioorg Med Chem Lett; 2020 Jul; 30(13):127213. PubMed ID: 32381396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
    Sang Z; Li Y; Qiang X; Xiao G; Liu Q; Tan Z; Deng Y
    Bioorg Med Chem; 2015 Feb; 23(4):668-80. PubMed ID: 25614117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigating 1,2,3,4,5,6-hexahydroazepino[4,3-b]indole as scaffold of butyrylcholinesterase-selective inhibitors with additional neuroprotective activities for Alzheimer's disease.
    Purgatorio R; de Candia M; Catto M; Carrieri A; Pisani L; De Palma A; Toma M; Ivanova OA; Voskressensky LG; Altomare CD
    Eur J Med Chem; 2019 Sep; 177():414-424. PubMed ID: 31158754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
    Xie SS; Wang X; Jiang N; Yu W; Wang KD; Lan JS; Li ZR; Kong LY
    Eur J Med Chem; 2015 May; 95():153-65. PubMed ID: 25812965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, Synthesis, Biological Evaluation, and Docking Study of Acetylcholinesterase Inhibitors: New Acridone-1,2,4-oxadiazole-1,2,3-triazole Hybrids.
    Mohammadi-Khanaposhtani M; Mahdavi M; Saeedi M; Sabourian R; Safavi M; Khanavi M; Foroumadi A; Shafiee A; Akbarzadeh T
    Chem Biol Drug Des; 2015 Dec; 86(6):1425-32. PubMed ID: 26077890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, anticholinesterase activity, molecular docking, and molecular dynamic simulation studies of 1,3,4-oxadiazole derivatives.
    Durmaz Ş; Evren AE; Sağlık BN; Yurttaş L; Tay NF
    Arch Pharm (Weinheim); 2022 Nov; 355(11):e2200294. PubMed ID: 35972839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease.
    Chalupova K; Korabecny J; Bartolini M; Monti B; Lamba D; Caliandro R; Pesaresi A; Brazzolotto X; Gastellier AJ; Nachon F; Pejchal J; Jarosova M; Hepnarova V; Jun D; Hrabinova M; Dolezal R; Zdarova Karasova J; Mzik M; Kristofikova Z; Misik J; Muckova L; Jost P; Soukup O; Benkova M; Setnicka V; Habartova L; Chvojkova M; Kleteckova L; Vales K; Mezeiova E; Uliassi E; Valis M; Nepovimova E; Bolognesi ML; Kuca K
    Eur J Med Chem; 2019 Apr; 168():491-514. PubMed ID: 30851693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel multi-targeted agents for Alzheimer's disease: Synthesis, biological evaluation, and molecular modeling of novel 2-[4-(4-substitutedpiperazin-1-yl)phenyl]benzimidazoles.
    Ozadali-Sari K; Tüylü Küçükkılınç T; Ayazgok B; Balkan A; Unsal-Tan O
    Bioorg Chem; 2017 Jun; 72():208-214. PubMed ID: 28478328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel tacrine-1,2,3-triazole hybrids: In vitro, in vivo biological evaluation and docking study of cholinesterase inhibitors.
    Najafi Z; Mahdavi M; Saeedi M; Karimpour-Razkenari E; Asatouri R; Vafadarnejad F; Moghadam FH; Khanavi M; Sharifzadeh M; Akbarzadeh T
    Eur J Med Chem; 2017 Jan; 125():1200-1212. PubMed ID: 27863370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of cyanopyridine-triazine hybrids as lead multitarget anti-Alzheimer agents.
    Maqbool M; Manral A; Jameel E; Kumar J; Saini V; Shandilya A; Tiwari M; Hoda N; Jayaram B
    Bioorg Med Chem; 2016 Jun; 24(12):2777-88. PubMed ID: 27157006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors.
    Wang L; Wang Y; Tian Y; Shang J; Sun X; Chen H; Wang H; Tan W
    Bioorg Med Chem; 2017 Jan; 25(1):360-371. PubMed ID: 27856236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, Characterization and Cholinesterase Inhibition Studies of New Arylidene Aminothiazolylethanone Derivatives.
    Channar PA; Shah MS; Saeed A; Khan SU; Larik FA; Shabir G; Iqbal J
    Med Chem; 2017; 13(7):648-653. PubMed ID: 28266279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and evaluation of novel 1,2,3-triazole-based acetylcholinesterase inhibitors with neuroprotective activity.
    Li JC; Zhang J; Rodrigues MC; Ding DJ; Longo JP; Azevedo RB; Muehlmann LA; Jiang CS
    Bioorg Med Chem Lett; 2016 Aug; 26(16):3881-5. PubMed ID: 27426301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease.
    Lu X; Qin N; Liu Y; Du C; Feng F; Liu W; Chen Y; Sun H
    Eur J Med Chem; 2022 Dec; 243():114729. PubMed ID: 36084535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, biological evaluation, and molecular dynamics of novel cholinesterase inhibitors as anti-Alzheimer's agents.
    Shamsimeymandi R; Pourshojaei Y; Eskandari K; Mohammadi-Khanaposhtani M; Abiri A; Khodadadi A; Langarizadeh A; Sharififar F; Amirheidari B; Akbarzadeh T; Lotfian H; Foroumadi A; Asadipour A
    Arch Pharm (Weinheim); 2019 Jul; 352(7):e1800352. PubMed ID: 31136018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and evaluation of novel multi-target-directed ligands for treatment of Alzheimer's disease based on coumarin and lipoic acid scaffolds.
    Jalili-Baleh L; Forootanfar H; Küçükkılınç TT; Nadri H; Abdolahi Z; Ameri A; Jafari M; Ayazgok B; Baeeri M; Rahimifard M; Abbas Bukhari SN; Abdollahi M; Ganjali MR; Emami S; Khoobi M; Foroumadi A
    Eur J Med Chem; 2018 May; 152():600-614. PubMed ID: 29763808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coumarin-thiazole and -oxadiazole derivatives: Synthesis, bioactivity and docking studies for aldose/aldehyde reductase inhibitors.
    Ibrar A; Tehseen Y; Khan I; Hameed A; Saeed A; Furtmann N; Bajorath J; Iqbal J
    Bioorg Chem; 2016 Oct; 68():177-86. PubMed ID: 27544072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, design and biological evaluation of novel highly potent tacrine congeners for the treatment of Alzheimer's disease.
    Hamulakova S; Janovec L; Hrabinova M; Kristian P; Kuca K; Banasova M; Imrich J
    Eur J Med Chem; 2012 Sep; 55():23-31. PubMed ID: 22818849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
    Hepnarova V; Korabecny J; Matouskova L; Jost P; Muckova L; Hrabinova M; Vykoukalova N; Kerhartova M; Kucera T; Dolezal R; Nepovimova E; Spilovska K; Mezeiova E; Pham NL; Jun D; Staud F; Kaping D; Kuca K; Soukup O
    Eur J Med Chem; 2018 Apr; 150():292-306. PubMed ID: 29533874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis, pharmacology and molecular docking on multifunctional tacrine-ferulic acid hybrids as cholinesterase inhibitors against Alzheimer's disease.
    Zhu J; Yang H; Chen Y; Lin H; Li Q; Mo J; Bian Y; Pei Y; Sun H
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):496-506. PubMed ID: 29405075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.